A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Nivolumab (Primary) ; Capecitabine; Irinotecan; Temsirolimus
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma
- Focus Adverse reactions
- Acronyms NivoPlus
- 23 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 23 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.